• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 10, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Coming soon: A blood test for Alzheimer's disease?

Bioengineer by Bioengineer
January 17, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

People with symptoms of Alzheimer’s disease (AD), such as cognitive difficulties, behavior changes and mood swings, may wait months or even years to get a definitive diagnosis. That’s because doctors lack a simple, accurate and inexpensive test for it. But according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society, researchers are getting much closer to developing the elusive blood test for AD.

About 5.5 million Americans are living with AD, according to the National Institute on Aging. Most do not seek treatment until their symptoms are well advanced, freelance contributor Jyoti Madhusoodanan writes. By then, substantial and irreversible damage to the brain has already occurred. Current tests for AD, such as positron emission tomography (PET) and lumbar puncture, are invasive, cost thousands of dollars and aren’t covered by most health insurance plans in the U.S. For nearly 20 years, researchers have been trying to develop a blood test for AD, but they’ve been stymied by the low amounts of potential biomarkers in blood.

Recently, new biomarkers and assays have moved a reliable blood test closer to the clinic. For example, instead of measuring the total amount of amyloid — the protein that forms clumps in the brains of AD patients — in blood, researchers can more accurately diagnose AD by looking at ratios of different peptides that form when amyloid breaks down. Sensitive new assays can detect smaller amounts of these peptides in blood. These and other developments have made many researchers optimistic that a blood test for AD will be available within the next five years. Such a test would not only aid in diagnosis, but might also help in the search for better AD treatments because it could identify participants for clinical trials.

###

The article was produced in partnership with ACS Central Science, ACS’ fully open-access journal. Read the original version here.

The article, “A blood test for Alzheimer’s disease draws near,” is freely available here.

The American Chemical Society, the world’s largest scientific society, is a not-for-profit organization chartered by the U.S. Congress. ACS is a global leader in providing access to chemistry-related information and research through its multiple databases, peer-reviewed journals and scientific conferences. ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies. Its main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact [email protected].

Follow us on Twitter | Facebook

Media Contact
Katie Cottingham
[email protected]
301-775-8455

Tags: AgingAlzheimerBiochemistryCell BiologyChemistry/Physics/Materials SciencesDiagnosticsGenetics
Share12Tweet8Share2ShareShareShare2

Related Posts

EVG7 Antibiotic Stops C. difficile, Spares Gut Bacteria

October 10, 2025
Upcoming Release: The Journal of Nuclear Medicine Ahead-of-Print Highlights – October 10, 2025

Upcoming Release: The Journal of Nuclear Medicine Ahead-of-Print Highlights – October 10, 2025

October 10, 2025

Proximity to Toxic Sites Associated with Increased Risk of Aggressive Breast Cancer

October 10, 2025

Solar Power Illuminates Path to a Fossil-Free Chemical Industry

October 10, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1196 shares
    Share 478 Tweet 299
  • New Study Reveals the Science Behind Exercise and Weight Loss

    102 shares
    Share 41 Tweet 26
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    96 shares
    Share 38 Tweet 24
  • Revolutionizing Optimization: Deep Learning for Complex Systems

    83 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

EVG7 Antibiotic Stops C. difficile, Spares Gut Bacteria

Revolutionizing Blood Cancer Treatment: Reprogramming Cancer Cell Death to Activate the Immune System

LED Light Targets and Destroys Cancer Cells While Protecting Healthy Tissue

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 63 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.